Which company develops and produces margetuximab?

Margetuximab (Margetuximab) is a new type of targeted anti-HER2 monoclonal antibody, mainly used to treat patients with HER2-positive advanced breast cancer. The drug was developed by MacroGenics Inc., an American biopharmaceutical company that focuses on developing innovative antibody therapies, especially in the field of tumor immunotherapy. It has strong technical strength and rich R&D experience. Margetuximab is one of the important products of MacroGenics in the field of anti-HER2 antibodies.

MacroGenicsThe company was founded in 2000 and is headquartered in Maryland, USA. It is a biopharmaceutical company that mainly develops and commercializes monoclonal antibodies and immunotherapy. The company is committed to promoting a variety of innovative drugs to clinical applications through independent research and development and partnerships. The development of macituximab began with the need to improve the immune effect of traditional HER2 antibodies (such as trastuzumab). MacroGenics used Fc engineering technology to transform the antibody to enhance its ability to bind to immune cells, thereby improving the anti-tumor effect.

In terms of production, the commercial production of margituximab is mainly handled byMacroGenics and its partners. The global production of the drug usually relies on contract manufacturing organizations (CMO) with advanced biopharmaceutical manufacturing capabilities to ensure product quality and supply chain stability. MacroGenics is also actively cooperating with large pharmaceutical companies to jointly promote the clinical trials, approval and marketing of margetuximab, so that it can benefit patients faster.

In general, margituximab is an innovative anti-HER2 monoclonal antibody developed by the American biotechnology company MacroGenics Inc., which combines advanced antibody engineering technology to improve efficacy. Its production and commercialization rely on MacroGenics's own and partners' manufacturing and marketing resource support, and is committed to providing better treatment options for HER2 positive breast cancer patients.

Reference materials:https://www.drugs.com